{"id":"levalbuterol-hcl-inhalation-solution","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Tremor"},{"rate":"5-10","effect":"Nervousness"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Tachycardia"},{"rate":"2-5","effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL1201061","moleculeType":"Small molecule","molecularWeight":"275.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levalbuterol is the active R-enantiomer of albuterol that binds to beta-2 adrenergic receptors on airway smooth muscle cells, triggering increased intracellular cAMP and causing bronchodilation. This rapidly opens constricted airways and improves airflow in patients with obstructive airway diseases. As the pure active enantiomer, levalbuterol may provide enhanced efficacy with potentially fewer side effects compared to racemic albuterol.","oneSentence":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:46.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm in patients with reversible obstructive airway disease"},{"name":"Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT00665600","phase":"PHASE3","title":"Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":257},{"nctId":"NCT02948959","phase":"PHASE3","title":"Evaluation of Dupilumab in Children With Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-04-21","conditions":"Asthma","enrollment":408},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT02414854","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04-27","conditions":"Asthma","enrollment":1902},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01312961","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-03","conditions":"Asthma","enrollment":104},{"nctId":"NCT00562159","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":439},{"nctId":"NCT00550550","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":345},{"nctId":"NCT00809757","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Asthma","enrollment":197},{"nctId":"NCT00667407","phase":"PHASE3","title":"Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2000-11","conditions":"Asthma","enrollment":627},{"nctId":"NCT00583947","phase":"PHASE2","title":"A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Asthma","enrollment":53},{"nctId":"NCT00667797","phase":"PHASE4","title":"Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-03","conditions":"Asthma, COPD","enrollment":486},{"nctId":"NCT00685126","phase":"PHASE3","title":"Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2001-02","conditions":"Reactive Airways Disease (RAD)","enrollment":117}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ASTHENIA"},{"count":1,"reaction":"ACUTE MYOCARDIAL INFARCTION"},{"count":1,"reaction":"ACUTE RESPIRATORY FAILURE"},{"count":1,"reaction":"BRONCHITIS"},{"count":1,"reaction":"CARDIAC FAILURE"},{"count":1,"reaction":"CARDIAC OUTPUT DECREASED"},{"count":1,"reaction":"CARDIOMEGALY"},{"count":1,"reaction":"CHRONIC OBSTRUCTIVE AIRWAYS DISEASE EXACERBATED"},{"count":1,"reaction":"DEHYDRATION"},{"count":1,"reaction":"DYSPNOEA"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xopenex UDV","Xopenex Inhalation Solution","R-albuterol"],"phase":"phase_3","status":"active","brandName":"Levalbuterol HCl Inhalation Solution","genericName":"Levalbuterol HCl Inhalation Solution","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing. Used for Acute bronchospasm in patients with reversible obstructive airway disease, Maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}